NEW YORK (GenomeWeb News) – Qiagen disclosed in its 2013 annual report filed with the US Securities and Exchange Commission that it acquired CLC Bio for $68.2 million, net of cash acquired. It added in the document that the deal was "not significant" to its overall consolidated financial statements. Qiagen announced the acquisition in October but had not disclosed the financial terms at that time.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.